Log in to search using one of your social media accounts:

 

NIH partners 11 drugmakers to accelerate cancer therapy research

(Reuters) - The National Institutes of Health said on Thursday it had partnered 11 biopharma companies to help advance a new class of drugs that uses the body's immune system to fight cancer.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news

Related Links:

Preclinical tumor models are the foundation of translational cancer research. For exploring fundamental biologic mechanisms or designing new cancer therapies, in  vitro and in vivo models are the indispensable test environments in which countless discoveries have been made. Conventional models rely on immortalized cell lines that are notable for their reproducibility, convenience, and ease of use. Although these approaches continue to be widely used, their limitations are well known. In particular, these models are often criticized as poor reproductions of clinical tumors.
Source: Journal of Vascular and Interventional Radiology : JVIR - Category: Radiology Authors: Tags: Research in Translation Source Type: research
Senolytic compounds are those capable of selectively destroying senescent cells. They are useful because the buildup of senescent cells over time is one of the root causes of aging. A number of mechanisms have been discovered by which senescent cells can be provoked into self-destruction, such as bcl-2 inhibition or interference in FOXO4-p53 interactions. These examples are fairly well understood. Other mechanisms are known but less well understood; they require more work in order to proceed on the production of improved senolytic compounds. In some cases, however, the primary mechanism of action of a compound found...
Source: Fight Aging! - Category: Research Authors: Tags: Daily News Source Type: blogs
Publication date: Available online 20 May 2018 Source:The Journal of Steroid Biochemistry and Molecular Biology Author(s): Cristina Amaral, Tiago Vieira Augusto, Elisiário Tavares-da-Silva, Fernanda M.F. Roleira, Georgina Correia-da-Silva, Natércia Teixeira The leading cause of cancer death in women around the world is breast cancer. The aromatase inhibitors (AIs) are considered a first-line treatment for estrogen receptor-positive (ER+) breast tumors, in postmenopausal women. Exemestane (Exe) is a powerful steroidal AI, however, despite its therapeutic success, Exe-acquired resistance may occur leading to t...
Source: The Journal of Steroid Biochemistry and Molecular Biology - Category: Biochemistry Source Type: research
Publication date: 1 August 2018 Source:Life Sciences, Volume 206 Author(s): Qian Zhou, Chaoqun You, Cong Zheng, Yawen Gu, Hongchao Gu, Rui Zhang, Hongshuai Wu, Baiwang Sun DNA is considered to be one of the most promising targets for anticancer agents. Acridine analogues have anticancer activity based on DNA binding and topoisomerases inhibition. However, due to the side effects, resistance and low bioavailability, a few have entered into clinical usage and the mechanisms of action are not fully understood. Novel acridine derivatives are needed for effective cancer therapy. A series of novel 3-nitroacridine-based derivati...
Source: Life Sciences - Category: Biology Source Type: research
Publication date: 1 September 2018 Source:Colloids and Surfaces B: Biointerfaces, Volume 169 Author(s): Yiwen Li, Huailin Yang, Jiuxu Yao, Haiyang Yu, Xin Chen, Peng Zhang, Chunsheng Xiao An amphiphilic biodegradable prodrug (PLG-g-mPEG/CPT) was synthesized by conjugating disulfide-containing camptothecin (CPT) to poly(L-glutamic acid)-graft-methoxy poly(ethylene glycol) (PLG-g-mPEG) through esterification reaction. The amphiphilic prodrugs could self-assemble into micellar nanoparticles and encapsulate doxorubicin (DOX) in aqueous solution at pH 7.4. The treatment of the nanoparticles with reducing glutathione (GSH) at c...
Source: Colloids and Surfaces B: Biointerfaces - Category: Biochemistry Source Type: research
Authors: Aqbi HF, Tyutyunyk-Massey L, Keim RC, Butler SE, Thekkudan T, Joshi S, Smith TM, Bandyopadhyay D, Idowu MO, Bear HD, Payne KK, Gewirtz DA, Manjili MH Abstract Breast cancer patients who initially respond to cancer therapies often succumb to distant recurrence of the disease. It is not clear why people with the same type of breast cancer respond to treatments differently; some escape from dormancy and relapse earlier than others. In addition, some tumor clones respond to immunotherapy while others do not. We investigated how autophagy plays a role in accelerating or delaying recurrence of neu-overexpressing...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Publication date: 15 August 2018 Source:Journal of Molecular Liquids, Volume 264 Author(s): Chunhuan Shi, Zhiqing Zhang, Fang Wang, Yuxia Luan Active targeting agents can identify patients with receptors overexpressed on the surface of cancer cells. The selective and efficient drug delivery to tumor cells can remarkably improve different cancer therapeutic effect. Folic acid (FA) conjugation is a facile approach for targeting folate receptor-expressing tissues for personalized treatment. In the present study, ethoxy poly(ethylene glycol)- folic acid (FA-PEG) is introduced as the potent targeting moieties in docetaxel (DTX...
Source: Journal of Molecular Liquids - Category: Molecular Biology Source Type: research
Publication date: Available online 19 May 2018 Source:Prostaglandins & Other Lipid Mediators Author(s): Fen Xu, Xiaoyan Zhou, Jian Hao, Hua Dai, Jian Zhang, Yuanqiao He, Hua Hao Epithelial-mesenchymal Transition (EMT) and migration play an important role in tumor progression, and lipoxin (LX), the ‘stop signal’ for inflammation, has been studied in basic research for its anti-inflammatory or inflammatory pro-resolving properties. Here, in the in vitro experiment, we showed that LXA4 could inhibit the EMT and migration in phorbol myristate acetate (PMA) or activated conditioned medium (ACM)-stimulated Hep3B...
Source: Prostaglandins and Other Lipid Mediators - Category: Lipidology Source Type: research
In this study, we found discrepancies in iNKT cell responses against two T cell-origin cell lines (Jurkat and Molt-4). Human iNKT cells exhibited more intensive cytotoxicity and less efficient cytokine production in response to Fas-bearing Jurkat cells than those to the Fas-negative tumor cells (Molt-4 and myeloid-derived K562). The imbalanced cytokine/cytotoxicity responses of iNKT cells against Jurkat cells were CD1d-dependent and relied mostly on Fas/FasL interaction. The impairment in cytokine production could be overcome by Fas/FasL blocking antibodies and exogenous IL-2. Elevated CD1d levels as well as CD1d and Fas c...
Source: Molecular Immunology - Category: Allergy & Immunology Source Type: research
RIMA Abstract Metastasis remains the most common cause of death in cancer patients. Inhibition of metalloproteinases (MMPs) is an interesting approach to cancer therapy because of their role in the degradation of extracellular matrix (ECM), cell-cell, and cell-ECM interactions, modulating key events in cell migration and invasion. Herein, we show the cytotoxic and antimetastatic effects of the third fraction (FR3) from Bauhinia variegata candida (Bvc) stem on human cervical tumor cells (HeLa) and human peripheral blood mononuclear cells (PBMCs). FR3 inhibited MMP-2 and MMP-9 activity, indicated by zymogram. This ...
Source: Biomed Res - Category: Research Authors: Tags: Biomed Res Int Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Health | National Institutes of Health (NIH)